You pull up a patient's history and see:
ANTI-Jkᵃ — IDENTIFIED 2019
Cool.
Today's antibody screen?
Negative.
So...the anti-Jkᵃ is gone, right?
Can we just give them ordinary crossmatch-compatible blood now?
Nope.
For a previously identified clinically significant red blood cell alloantibody, a negative antibody screen does not erase the antibody history. The patient should still be treated as having that antibody when compatible RBCs are selected.
This is because red-cell antibodies have an annoying habit of doing something known as evanescence.
They disappear.
Until they don't.
What Is Antibody Evanescence?
After exposure to a foreign RBC antigen through transfusion or pregnancy, some patients mount an alloimmune response and form an antibody.
Maybe it's anti-E.
Maybe anti-Fyᵃ.
Maybe everyone's favorite:
anti-Jkᵃ.
Initially, there may be plenty of circulating antibody for the Blood Bank to detect.
But antibody concentrations don't necessarily remain elevated forever.
Without continued antigenic stimulation, the amount of circulating antibody may gradually decline. Eventually, its concentration can fall below the analytic detection threshold of routine antibody screening.
At that point:
The antibody screen becomes negative.
That doesn't necessarily mean the immune response has been erased.
It means the assay can no longer detect enough circulating antibody to produce a positive result.
Antibody evanescence is common enough to be a significant transfusion-safety issue. In a 2020 study, 35% of identified RBC alloantibodies eventually became undetectable during follow-up. Different antibody specificities behaved very differently, with anti-Jkᵃ among those particularly likely to disappear.
An older long-term study similarly found substantial antibody loss over time and estimated that approximately half of the antibodies it followed would become undetectable within several years.
And a 2025 study again found especially high evanescence among anti-Jkᵃ, along with anti-C and anti-M.
So:
Negative today does not necessarily mean never existed.
The Immune System Remembers
Let's say our patient is Jk(a−).
Years ago, they received Jk(a+) blood and produced anti-Jkᵃ.
Eventually, their circulating antibody concentration falls low enough that today's antibody screen is completely negative.
Now the patient returns to another hospital and needs two RBC units.
If nobody knows about the historical anti-Jkᵃ, those units might very well be:
Jk(a+).
The current antibody screen won't stop you.
The crossmatch may even look perfectly compatible.
So the units are transfused.
But the patient's immune system has seen Jkᵃ before.
Re-exposure can trigger an anamnestic—or secondary—immune response, producing a rapid increase in antibody concentration. The newly produced antibody then binds the transfused antigen-positive RBCs and shortens their survival. This is the classic setup for a delayed hemolytic transfusion reaction (DHTR). Canadian Blood Services describes exactly this sequence: an alloantibody develops, fades below detection, antigen-positive RBCs are subsequently transfused, and an anamnestic response follows days to weeks later.
The patient's antibody didn't need to be detectable at the time of transfusion to cause trouble later.
Kidd Being Kidd
This phenomenon isn't unique to Kidd antibodies.
Antibodies in several systems can disappear over time.
But the Kidd system has developed a particularly nasty reputation for it.
Anti-Jkᵃ and anti-Jkᵇ are well known for becoming difficult or impossible to detect after the initial immune response. In a large multicenter study of transfused patients, Kidd antibodies were disproportionately found relatively soon after transfusion, while antibodies such as anti-K and anti-Fyᵃ remained more commonly detectable years later.
That behavior creates the perfect conditions for a delayed reaction:
Anti-Jkᵃ forms.
↓
Anti-Jkᵃ fades.
↓
Screen becomes negative.
↓
Patient receives Jk(a+) RBCs.
↓
Anamnestic anti-Jkᵃ response develops.
↓
Transfused cells start disappearing.
And Kidd antibodies can activate complement, which adds another layer to their ability to produce clinically important hemolysis.
There's a reason Blood Bankers get twitchy when they see historical anti-Jkᵃ buried ten years back in the patient record.
What Does a Delayed Hemolytic Transfusion Reaction Look Like?
The transfusion itself may have been completely uneventful.
The patient receives the RBCs.
The nurse documents completion.
Everybody goes home happy.
Then several days later, the patient's hemoglobin isn't where it should be.
Or it increased after transfusion and then mysteriously starts falling again.
You may see:
falling hemoglobin
increased indirect bilirubin
increased LDH
decreased haptoglobin
a newly positive DAT
a newly positive antibody screen
an eluate demonstrating the offending alloantibody
jaundice, fever, or dark urine in some patients
Sometimes the reaction is primarily serologic: the antibody reappears and transfused cells are sensitized without dramatic clinical hemolysis.
Other times, the patient develops a genuine delayed hemolytic transfusion reaction.
Canadian Blood Services lists E, Jkᵃ, c, Fyᵃ, and K among commonly implicated specificities in delayed reactions.
This Is Why We Check the History
One of the first things your LIS does during a type and screen isn't glamorous at all:
It looks backward.
What was this patient's previous ABO/Rh type?
Have they had typing discrepancies?
Do they have special product requirements?
And:
Have they ever had a clinically significant antibody?
That history can be more important than today's negative antibody screen.
The publicly available AABB Fundamental Standards explicitly require review of historical clinically significant antibodies before transfusion and state that when a clinically significant antibody is detected or the recipient has a history of one, RBC components should lack the corresponding antigen and/or meet appropriate serologic compatibility requirements.
Canadian Blood Services similarly states that antigen-negative RBCs should be provided when the antibody history is known regardless of the current antibody-screen result.
So your patient with:
Historical anti-Jkᵃ
and
Current screen: NEGATIVE
still gets:
Jk(a−) RBCs.
The screen didn't overrule the history.
It Also Changes the Crossmatch
This is one of those situations where:
Negative screen ≠ uncomplicated patient.
A patient with a negative current antibody screen and no history of clinically significant antibodies can generally qualify for electronic crossmatch when the other requirements are satisfied.
A patient with a negative screen but a history of a clinically significant antibody does not simply become equivalent to that patient.
Canadian Blood Services specifically notes that electronic crossmatching is limited to patients with a negative current antibody screen and no history of a clinically significant antibody. Patients with clinically significant antibodies require selection of antigen-negative units and serologic compatibility testing.
So that tiny historical entry from 2017 can still completely change today's Blood Bank workflow.
“But We Can't Detect It Anymore”
That's the whole point.
If the antibody were still easily detectable, none of this would be especially interesting.
The dangerous situation is precisely the one where today's testing says:
Nothing detected.
If you didn't know the patient's previous results, you would have no laboratory reason to search for Jk(a−), Fy(a−), E-negative, or whatever antigen-negative blood they previously required.
The historical result supplies information the current specimen no longer contains.
That's why antibody histories should not casually be deleted because:
the screen became negative
a different methodology doesn't detect the antibody
the antibody hasn't appeared in years
a subsequent hospital couldn't reproduce it
An antibody can be historically real and currently undetectable at the same time.
Those aren't contradictory statements.
Does Every Historical Antibody Get “Honored Forever”?
Here's where the wording needs a little nuance.
We're talking specifically about previously established, clinically significant alloantibodies.
Not every reaction that has ever appeared in the Blood Bank should automatically result in lifelong antigen-negative transfusion.
A history might instead involve:
passive anti-D following Rh immune globulin
a clinically insignificant cold antibody
nonspecific reactivity
an antibody of undetermined specificity
an autoantibody
a result later demonstrated to be erroneous
Those situations have to be interpreted appropriately.
But once a genuine clinically significant alloantibody has been established, the fact that it later becomes undetectable is expected biology—not evidence that the original identification was wrong.
That's the distinction.
There Is One Giant Problem: What Happens When the Patient Changes Hospitals?
Here's where modern transfusion medicine gets surprisingly primitive.
Your hospital may have a beautiful permanent record showing:
ANTI-Jkᵃ — 2012
But then the patient moves.
They present to another health system.
That hospital draws a type and screen.
Negative.
Unless somebody obtains the previous transfusion history, the new hospital may have absolutely no idea that anti-Jkᵃ ever existed.
The patient's immune system remembers.
The new hospital's LIS does not.
This problem is significant enough that AABB has specifically promoted development of a national transfusion-antibody registry to improve sharing of antibody histories and reduce delayed hemolytic reactions.
It is also why patients with clinically significant antibodies may be given antibody cards or other documentation and encouraged to tell future hospitals about their transfusion history. Canadian Blood Services specifically recommends that patients know and communicate their antibody histories when receiving care elsewhere.
For something as technologically complicated as modern medicine, an astonishing amount of transfusion safety can still depend on:
“Hey, by the way, another hospital told me years ago that I have anti-Kidd something.”
And suddenly somebody in the Blood Bank is on the phone requesting records.
Why Can't We Just Screen Everybody After Every Transfusion?
Another reason antibodies disappear from the historical record is that you first have to detect them at all.
Patients aren't routinely brought back to the Blood Bank every few weeks after transfusion just to see whether they've formed a new alloantibody.
A patient can therefore:
receive an antigen-positive RBC
↓
form an alloantibody several weeks later
↓
never have an antibody screen during the period when it is readily detectable
↓
allow the antibody to eventually evanesce
↓
return years later with a negative screen
In that situation, there isn't even a historical antibody for the Blood Bank to honor.
The antibody existed.
Nobody ever caught it.
A multicenter study examining alloantibody detection after transfusion specifically warned that because patients aren't routinely screened at set intervals after transfusion, some newly formed antibodies are never documented before the next transfusion episode.
That's one of the limitations of pretransfusion antibody screening:
We only know the antibodies we've had an opportunity to see.
The Takeaway
A red-cell alloantibody can disappear from routine testing.
That does not mean the patient's immune system has forgotten the antigen.
If a patient with an evanescent antibody is transfused with antigen-positive RBCs, re-exposure can produce an anamnestic antibody response and lead to a delayed hemolytic transfusion reaction.
That's why:
Historical clinically significant antibodies still matter.
If your patient had anti-Jkᵃ ten years ago and today's antibody screen is negative, you don't delete the anti-Jkᵃ and move on.
You select Jk(a−) blood.
Because today's antibody screen answers:
“Can I detect this antibody in the patient's plasma right now?”
The patient's antibody history answers a different—and sometimes much more important—question:
“Has this patient's immune system ever demonstrated that it can make this antibody?”
And when the answer to that second question is yes:
Believe it.
Especially if it's Kidd.
